REAGAN ROBBINS: Open Payments
NPI 1306590393 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$578 in 33 payments from 6 companies in 2025. Trend: 2023 $965 · 2024 $556 · 2025 $578
Food & beverage: $578
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $455 |
| GENZYME CORPORATION | 2 | $53 |
| Janssen Biotech, Inc. | 1 | $23 |
| PFIZER INC. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
Products named: RINVOQ, CREON, MAVYRET, DUPIXENT, LINZESS, TREMFYA, XELJANZ, EOHILIA.
Industry payments across IN — which companies pay providers there.
